<DOC>
	<DOCNO>NCT01010672</DOCNO>
	<brief_summary>The study evaluate efficacy Ridaforolimus administer maintenance therapy patient metastatic bone soft-tissue sarcoma Japan .</brief_summary>
	<brief_title>Phase II Study Ridaforolimus ( MK-8669 ) With Metastatic Bone Soft-tissue Sarcoma Patients ( MK-8669-030 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Documented histologic diagnosis bone softtissue sarcoma metastasize , derive benefit follow chemotherapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Completed prior chemotherapy last dose receive least 3 12 week prior randomization Adequate organ bone marrow function Presence brain central nervous system ( CNS ) metastases , unless successfully treat Prior therapy rapamycin rapamycin analog Ongoing toxicity associate prior anticancer therapy History current evidence clinically significant disease might confound result study , complicate interpretation study result , interfere patient 's participation , pose additional risk patient</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>